Goldman Sachs’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Goldman Sachs’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-204,858	Closed	-$22M	–	6222
2023 Q1	$22M	Sell	204,858 -164,266	-45%	-$18.9M	0.01%	1741
2022 Q4	$40.6M	Buy	369,124 +127,134	+53%	+$8.24M	0.01%	1338
2022 Q3	$14.3M	Buy	241,990 +29,552	+14%	+$1.35M	﹤0.01%	2167
2022 Q2	$6M	Sell	212,438 -85,290	-29%	-$2.47M	﹤0.01%	2976
2022 Q1	$11.2M	Buy	297,728 +259,436	+678%	+$10.3M	﹤0.01%	2575
2021 Q4	$1.51M	Sell	38,292 -131,442	-77%	-$4.11M	﹤0.01%	4488
2021 Q3	$4.02M	Buy	+169,734	New	+$4.01M	﹤0.01%	3538
2021 Q2	–	Sell	-59,083	Closed	-$1.08M	–	6641
2021 Q1	$1.08M	Buy	+59,083	New	+$1.22M	﹤0.01%	4551

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Goldman Sachs's RXDX Position: Q2 2023 in Review

Goldman Sachs sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 204,858 shares — an estimated $22M sold.

Goldman Sachs first reported a position in RXDX in Q1 2021 and held it in 8 quarters. The position peaked at $40.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Goldman Sachs reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 204,858 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $22M.
Goldman Sachs first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Goldman Sachs's Prometheus Biosciences, Inc. Common Stock position peaked at $40.6M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.